M Ducreux

Summary

Affiliation: Institut Gustave Roussy
Country: France

Publications

  1. ncbi request reprint Emerging drugs in pancreatic cancer
    Michel Ducreux
    Unité de Gastroentérologie, Institut Gustave Roussy, Villejuif, France
    Expert Opin Emerg Drugs 9:73-89. 2004
  2. ncbi request reprint Combination chemotherapy in advanced small bowel adenocarcinoma
    Christophe Locher
    Gastroenterology Unit, Institut Gustave Roussy, Villejuif, France
    Oncology 69:290-4. 2005
  3. ncbi request reprint Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study
    Samy Louafi
    Service d Hepato gastro enterologie, Groupe Hospitalier Pitie Salpetriere, Paris, France
    Cancer 109:1384-90. 2007
  4. ncbi request reprint Treatment of advanced pancreatic cancer
    Michel Ducreux
    Gastroenterology Unit, Institut Gustave Roussy, 39 rue Camille Desmoulins, Villejuif 94805, France
    Semin Oncol 34:S25-30. 2007
  5. pmc Developments in treating metastatic colorectal cancer: Recent international reports from ASCO 2007 and 2008
    Michel Ducreux
    Gastro Intestinal Unit, Institut Gustave Roussy, Villejuif Cedex, France Department of Oncology, Paul Brousse University Hospital, Villejuif, France Paris Sud XI University, Le Kremlin Bicetre, France
    Clin Exp Gastroenterol 2:13-9. 2009
  6. doi request reprint Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizu
    M Ducreux
    Department of Medicine, Institut Gustave Roussy, Villejuif, Universite Paris Sud, Le Kremlin Bicetre, France
    Eur J Cancer 49:1236-45. 2013
  7. pmc Docetaxel- and 5-FU-concurrent radiotherapy in patients presenting unresectable locally advanced pancreatic cancer: a FNCLCC-ACCORD/0201 randomized phase II trial's pre-planned analysis and case report of a 5.5-year disease-free survival
    Lucie Oberic
    Institut Gustave Roussy, Villejuif, France
    Radiat Oncol 6:124. 2011
  8. ncbi request reprint Randomised trial comparing three different schedules of infusional 5FU and raltitrexed alone as first-line therapy in metastatic colorectal cancer. Final results of the Fédération Francophone de Cancérologie Digestive (FFCD) 9601 trial
    M Ducreux
    Institut Gustave Roussy, Villejuif, France
    Oncology 70:222-30. 2006
  9. ncbi request reprint [Screening and early diagnosis of other cancers (non-small cell lung carcinoma, urologic cancers, liver cancer and melanoma)]
    Michel Ducreux
    Departement de Medecine, Institut Gustave Roussy, 94805 Villejuif
    Rev Prat 60:219-23. 2010
  10. ncbi request reprint A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma
    M Ducreux
    Institut Gustave Roussy, Service d Oncologie Digestive, Villejuif, France
    Ann Oncol 13:1185-91. 2002

Detail Information

Publications134 found, 100 shown here

  1. ncbi request reprint Emerging drugs in pancreatic cancer
    Michel Ducreux
    Unité de Gastroentérologie, Institut Gustave Roussy, Villejuif, France
    Expert Opin Emerg Drugs 9:73-89. 2004
    ....
  2. ncbi request reprint Combination chemotherapy in advanced small bowel adenocarcinoma
    Christophe Locher
    Gastroenterology Unit, Institut Gustave Roussy, Villejuif, France
    Oncology 69:290-4. 2005
    ..To assess the efficacy of 5-fluorouracil (5-FU) and either platinum compounds or irinotecan in patients with advanced small bowel adenocarcinoma (SBA), for whom data on the efficacy of chemotherapy are scarce...
  3. ncbi request reprint Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study
    Samy Louafi
    Service d Hepato gastro enterologie, Groupe Hospitalier Pitie Salpetriere, Paris, France
    Cancer 109:1384-90. 2007
    ..In a Phase II trial involving previously untreated patients with advanced HCC, the more favorable schedule from a previous pilot study was evaluated...
  4. ncbi request reprint Treatment of advanced pancreatic cancer
    Michel Ducreux
    Gastroenterology Unit, Institut Gustave Roussy, 39 rue Camille Desmoulins, Villejuif 94805, France
    Semin Oncol 34:S25-30. 2007
    ..Further advances will probably be made with combinations of targeted therapies. Better understanding of the carcinogenesis of this very aggressive cancer is also needed...
  5. pmc Developments in treating metastatic colorectal cancer: Recent international reports from ASCO 2007 and 2008
    Michel Ducreux
    Gastro Intestinal Unit, Institut Gustave Roussy, Villejuif Cedex, France Department of Oncology, Paul Brousse University Hospital, Villejuif, France Paris Sud XI University, Le Kremlin Bicetre, France
    Clin Exp Gastroenterol 2:13-9. 2009
    ..Major questions regarding optimal management of mCRC await resolution...
  6. doi request reprint Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizu
    M Ducreux
    Department of Medicine, Institut Gustave Roussy, Villejuif, Universite Paris Sud, Le Kremlin Bicetre, France
    Eur J Cancer 49:1236-45. 2013
    ....
  7. pmc Docetaxel- and 5-FU-concurrent radiotherapy in patients presenting unresectable locally advanced pancreatic cancer: a FNCLCC-ACCORD/0201 randomized phase II trial's pre-planned analysis and case report of a 5.5-year disease-free survival
    Lucie Oberic
    Institut Gustave Roussy, Villejuif, France
    Radiat Oncol 6:124. 2011
    ..We report here the results of the docetaxel plus 5 FU regimen stopped according to the interim analysis. The docetaxel plus cisplatin arm was continued...
  8. ncbi request reprint Randomised trial comparing three different schedules of infusional 5FU and raltitrexed alone as first-line therapy in metastatic colorectal cancer. Final results of the Fédération Francophone de Cancérologie Digestive (FFCD) 9601 trial
    M Ducreux
    Institut Gustave Roussy, Villejuif, France
    Oncology 70:222-30. 2006
    ....
  9. ncbi request reprint [Screening and early diagnosis of other cancers (non-small cell lung carcinoma, urologic cancers, liver cancer and melanoma)]
    Michel Ducreux
    Departement de Medecine, Institut Gustave Roussy, 94805 Villejuif
    Rev Prat 60:219-23. 2010
    ..Some cancers did not follow this rule because, for instance, the screening and early diagnosis of lung cancer among smokers is still a failure even when using the scanner...
  10. ncbi request reprint A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma
    M Ducreux
    Institut Gustave Roussy, Service d Oncologie Digestive, Villejuif, France
    Ann Oncol 13:1185-91. 2002
    ..5% response rate and a 29% survival rate at 1 year. The present study aimed to compare FUP with 5-FU alone, which was the control arm in former Mayo Clinic trials...
  11. ncbi request reprint [Docetaxel and gastric cancer]
    Michel Ducreux
    Unité de Gastroentérologie, Institut Gustave Roussy, rue Camille Desmoulins, 94805 Villejuif
    Bull Cancer 91:257-61. 2004
    ..With a high activity in terms of radiosensitization, docetaxel could also become a major drug in the design of new radiochemotherapy protocols for neoadjuvant or adjuvant disease...
  12. doi request reprint Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer
    Michel Ducreux
    Department of Medicine, Gustave Roussy Institute, Villejuif, France
    Int J Cancer 128:682-90. 2011
    ..47%), febrile neutropenia (0% vs. 6%) and neuropathy (11% vs. 26%) than FOLFOX-6 patients. We conclude that XELOX is non-inferior in terms of efficacy to FOLFOX-6 in the first-line treatment of MCRC, but has a different toxicity profile...
  13. doi request reprint Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trial
    Michel Ducreux
    Institut Gustave Roussy, Paris, France
    Lancet Oncol 12:1032-44. 2011
    ..Our aim was to investigate whether combination treatment is better than the sequential administration of the same drugs in patients with advanced colorectal cancer...
  14. ncbi request reprint [Non-invasive imaging tools in colorectal cancer]
    Michel Ducreux
    Service de cancérologie digestive, Institut Gustave Roussy, 94805 Villejuif Cedex, France
    Rev Prat 60:1071-3. 2010
    ..Its role in early determination of therapeutic response should be evaluated...
  15. ncbi request reprint [Treatment strategy of neuroendocrine tumors]
    Michel Ducreux
    Unité de gastroentérologie Institut Gustave Roussy 94805 Villejuif
    Rev Prat 52:290-6. 2002
    ..Gastrinoma and other pancreatic tumours arising in the context of multiple endocrine neoplasia type I disease need a specific therapeutic strategy...
  16. ncbi request reprint [Colon and rectal tumours]
    Michel Ducreux
    Service d Oncologie Digestive, Institut Gustave Roussy, 94805 Villejuif
    Rev Prat 55:1241-7. 2005
  17. ncbi request reprint Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer
    Michel Ducreux
    Gastrointestinal Unit, Institut Gustave Roussy, 94805 Villejuif Cedex, France
    J Clin Oncol 23:4881-7. 2005
    ....
  18. doi request reprint [Is it possible to individualize prescription of medical treatment in colorectal cancer? The clinician point of view]
    Michel Ducreux
    Unité de cancérologie digestive, Institut Gustave Roussy, Département de cancérologie, Hopital Paul Brousse, Villejuif, université de médecine Paris XI, Kremlin Bicetre
    Bull Cancer 95:931-4. 2008
    ..It must be emphasised that, for the first time in 2008, it is possible to prescribe targeted therapies to a specific "targeted" group of patients with metastatic colorectal cancer...
  19. ncbi request reprint The multidisciplinary management of gastrointestinal cancer. Pancreatic cancer: from pathogenesis to cure
    Michel Ducreux
    Unité de Gastroentérologie, Departement de Medecine, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
    Best Pract Res Clin Gastroenterol 21:997-1014. 2007
    ..For advanced disease, chemotherapy alone has given very disappointing results. A multidisciplinary approach combining biological assessment of targets with clinical trials to evaluate new targeted drugs should be considered...
  20. ncbi request reprint A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial
    M Ducreux
    Unité de Gastroentérologie, Institut Gustave Roussy, rue Camille Desmoulins, 94805 Villejuif Cedex, France
    Eur J Cancer 41:398-403. 2005
    ..These results are not sufficient to start a phase III trial. However, our group is planning a phase III trial comparing 5FU+folinic acid versus the same schedule+oxaliplatin a platinum analogue...
  21. doi request reprint High-dose irinotecan plus LV5FU2 or simplified LV5FU (HD-FOLFIRI) for patients with untreated metastatic colorectal cancer: a new way to allow resection of liver metastases?
    Michel Ducreux
    Institut Gustave Roussy, Villejuif, France
    Oncology 74:17-24. 2008
    ..Conclusion: HD-irinotecan plus LV5FU2 or HD-FOLFIRI is feasible and achieved a high response rate and postsurgery complete response rate...
  22. ncbi request reprint Efficacy of intraperitoneal chemohyperthermia with oxaliplatin in colorectal peritoneal carcinomatosis. Preliminary results in 24 patients
    D Elias
    Department of Surgical Oncology, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
    Ann Oncol 15:781-5. 2004
    ..We report preliminary results on survival in a phase II study using oxaliplatin (LOHP)...
  23. ncbi request reprint Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy
    D Elias
    Department of Oncological Surgery, Gustave Roussy Institute, Villejuif, France
    Cancer 92:71-6. 2001
    ..A new approach that combines maximal surgery with maximal regional chemotherapy has potential to cure selected patients who have colorectal PC. The authors have reported the oncologic results of this combined treatment...
  24. ncbi request reprint Hepatic arterial infusion using pirarubicin combined with systemic chemotherapy: a phase II study in patients with nonresectable liver metastases from colorectal cancer
    D Fallik
    Institut Gustave Roussy, Villejuif, France
    Ann Oncol 14:856-63. 2003
    ..A prospective phase II study was performed to determine the feasibility, efficacy and safety of arterial hepatic infusion (HAI) using pirarubicin combined with intravenous chemotherapy...
  25. ncbi request reprint Heated intra-operative intraperitoneal oxaliplatin plus irinotecan after complete resection of peritoneal carcinomatosis: pharmacokinetics, tissue distribution and tolerance
    D Elias
    Department of Surgical Oncology, Institut Gustave Roussy Comprehensive Cancer Center, Villejuif, France
    Ann Oncol 15:1558-65. 2004
    ..The purpose of this study was to report the pharmacokinetics (PK) and tolerance profile of intraoperative intraperitoneal chemo-hyperthermia (IPCH) with oxaliplatin and irinotecan...
  26. ncbi request reprint Irinotecan in metastatic colorectal cancer: dose intensification and combination with new agents, including biological response modifiers
    M Ducreux
    Institut Gustave Roussy, Villejuif, France
    Ann Oncol 14:ii17-23. 2003
    ..In vitro, the cyclin-dependent kinase inhibitor flavopiridol enhances the induction of apoptosis by chemotherapy. Clinically, it can safely be administered with irinotecan, and studies in CRC are planned...
  27. doi request reprint Combined liver surgery and RFA for patients with gastroenteropancreatic endocrine tumors presenting with more than 15 metastases to the liver
    D Elias
    Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, Cedex, France
    Eur J Surg Oncol 35:1092-7. 2009
    ..It is an extensive application of the current guidelines...
  28. doi request reprint Taking into account successive treatment lines in the analysis of a colorectal cancer randomised trial
    J Pénichoux
    Biostatistics and Epidemiology Unit, Institut de Cancerologie Gustave Roussy, Villejuif, France
    Eur J Cancer 49:1882-8. 2013
    ..7 [1.4-2.1]). Overall, this study suggests that starting with less toxic first-line treatment is a valid option since it does not exert a deleterious effect on the risk of overall progression or death...
  29. doi request reprint Clinical value of circulating endothelial cell levels in metastatic colorectal cancer patients treated with first-line chemotherapy and bevacizumab
    D Malka
    Gastrointestinal Oncology Unit, Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 23:919-27. 2012
    ..We investigated whether circulating endothelial cells (CECs) predict clinical outcome of first-line chemotherapy and bevacizumab in metastatic colorectal cancer (mCRC) patients...
  30. doi request reprint The differential response to chemotherapy of ovarian metastases from colorectal carcinoma
    D Goere
    Department of Surgical Oncology, Institut Gustave Roussy, 39, rue Camille Desmoulins, 94805 Villejuif, Cedex, France
    Eur J Surg Oncol 34:1335-9. 2008
    ....
  31. doi request reprint Value of cardiophrenic angle lymph node for the diagnosis of colorectal peritoneal carcinomatosis
    C Caramella
    Department of Radiology, Gustave Roussy Institute, Villejuif, France Electronic address
    Eur J Cancer 49:3798-805. 2013
    ..Cardiophrenic angle lymph nodes (CPALN) have been reported in patients with abdominopelvic malignancies. We aimed to assess whether the presence of CPALN is associated with peritoneal carcinomatosis (PC) in colorectal cancer...
  32. ncbi request reprint Impact of chromogranin A measurement in the work-up of neuroendocrine tumors
    E Baudin
    Department of Nuclear Medicine and Endocrine Tumors, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 12:S79-82. 2001
    ..Both tumor burden and secretory activity should be taken into account when interpreting CgA results...
  33. ncbi request reprint Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU, and infusional 5-FU alone in advanced pancreatic carcinoma patients
    M Ducreux
    Institut Gustave Roussy, Villejuif, France
    Ann Oncol 15:467-73. 2004
    ..A randomized phase II, open-label multicenter study evaluating oxaliplatin alone (OXA), infusional 5-fluorouracil alone (5-FU) and an oxaliplatin/infusional 5-FU combination (OXFU) in untreated, advanced pancreatic carcinoma (APC)...
  34. ncbi request reprint Optimization of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of leucovorin, 5-FU and cisplatin (LV5FU2-P regimen) in patients with biliary tract carcinoma
    J Taieb
    Departement de Medecine, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 13:1192-6. 2002
    ..Unresectable biliary tract carcinoma (BTC) is associated with a very poor prognosis. To improve efficacy and tolerance of the 5-fluorouracil (5-FU)/cisplatin combination in BTC, we designed a new therapeutic schedule, the LV5FU2-P regimen...
  35. ncbi request reprint Prognostic factors for chemoembolization in liver metastasis from endocrine tumors
    A Roche
    Department of Interventional Radiology, Institut Gustave Roussy, Villejuif Cedex, France
    Hepatogastroenterology 51:1751-6. 2004
    ..The aims of this study were to assess response rates, evaluate side effects and determine prognostic factors for both response and toxicity in patients with liver metastasis from endocrine tumors treated with chemoembolization...
  36. ncbi request reprint Radiotherapy for localized rectal cancer
    E Deutsch
    Department of Radiation Therapy Institut Gustave Roussy, Villejuif, France
    Ann Oncol 18:ix105-13. 2007
  37. pmc Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin
    E Mitry
    Department of Gastroenterology, Institut Gustave Roussy, Villejuif, France
    Br J Cancer 81:1351-5. 1999
    ..However, the prognosis remains poor with a 2-year survival lower than 20% confirming that new therapeutic strategies have to be developed...
  38. ncbi request reprint [Resectional treatment of peritoneal carcinomatosis followed by intraperitoneal chemotherapy, practical aspects]
    D Elias
    Département de chirurgie digestive carcinologique, Institut Gustave Roussy, Villejuif
    J Chir (Paris) 140:270-6. 2003
    ..If these conditions can be met, peritoneal metastases can be definitively cured in two thirds of colorectal PC and pseudomyxoma peritonei, and in nearly half of mesotheliomas...
  39. pmc Tumour-infiltrating CD68+ and CD57+ cells predict patient outcome in stage II-III colorectal cancer
    N Chaput
    Centre of clinical investigation in biotherapy CIC BT 507, Institut Gustave Roussy, Villejuif, France
    Br J Cancer 109:1013-22. 2013
    ..The aim of our study was to evaluate the prognostic role of immunological microenvironnement in stage II-III CRC patients...
  40. pmc Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial
    V Boige
    Gastrointestinal Oncology Unit, Institut Gustave Roussy, Villejuif, France
    Br J Cancer 97:862-7. 2007
    ..However, the manageable toxicity profile and the encouraging disease control rate deserve further attention for this convenient, outpatient-based chemotherapy regimen...
  41. ncbi request reprint Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours
    T Aparicio
    , Institut Gustave Roussy, 94805, Villejuif, France
    Eur J Cancer 37:1014-9. 2001
    ..A slow tumour growth rate before treatment is predictive of a good response to somatostatin analogues which could be considered an option for first-line treatment...
  42. doi request reprint Central retroperitoneal recurrences from colorectal cancer: are lymph node and locoregional recurrences the same disease?
    F Dumont
    Department of Digestive Oncological Surgery, Institut Gustave Roussy, Villejuif, France
    Eur J Surg Oncol 38:611-6. 2012
    ..A CRR is sometimes defined as a locoregional recurrence (LR) and sometimes as a lymph node recurrence (NR). This study was conducted to determine the nature of CRR and evaluate prognostic factors after complete CRR resection...
  43. ncbi request reprint [Assessment of the cost of first line chemotherapy in metastatic colorectal cancer. Preliminary results in the FFCD 9601 trial]
    C Locher
    , Institut Gustave-Roussy, Villejuif, France
    Gastroenterol Clin Biol 25:749-54. 2001
    ..In this study, toxicity was probably overestimated due to the small number of patients. More patients are necessary in order to better estimate the cost of toxicity of these chemotherapies...
  44. ncbi request reprint Preliminary results of intraperitoneal chemohyperthermia with oxaliplatin in peritoneal carcinomatosis of colorectal origin
    D Elias
    Department of Surgical Oncology, Institut Gustave Roussy, Villejuif, France
    Br J Surg 91:455-6. 2004
  45. ncbi request reprint Screening for multiple endocrine neoplasia type 1 and hormonal production in apparently sporadic neuroendocrine tumors
    E Baudin
    Nuclear Medicine, Institut Gustave Roussy, Villejuif, France
    J Clin Endocrinol Metab 84:69-75. 1999
    ..Routine hormonal measurements should depend on the primary site. NSE, 5-HIAA, CT, and alphaGP should be routinely measured in foregut-derived NET; only serum NSE and 5-HIAA measurements are recommended in midgut-derived NET...
  46. ncbi request reprint Prognostic factors after surgery of primary resectable gastrointestinal stromal tumours
    T Aparicio
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Eur J Surg Oncol 30:1098-103. 2004
    ..To analyse the prognostic factors of gastrointestinal stromal tumours (GIST) after a complete resection of the primary tumour...
  47. doi request reprint Intra-arterial hepatic chemotherapy: a comparison of percutaneous versus surgical implantation of port-catheters
    F Deschamps
    Department of Interventional Radiology, Gustave Roussy Institut, Villejuif, France
    Cardiovasc Intervent Radiol 34:973-9. 2011
    ..To compare retrospectively the safety and efficacy of percutaneous and surgical implantations of port-catheters for intra-arterial hepatic chemotherapy (IAHC)...
  48. ncbi request reprint Hepatic arterial infusion of oxaliplatin and intravenous LV5FU2 in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure
    Valerie Boige
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Ann Surg Oncol 15:219-26. 2008
    ..Whether this regimen could be beneficial after systemic chemotherapy failure is unknown...
  49. pmc Tumor marker evolution: comparison with imaging for assessment of response to chemotherapy in patients with colorectal liver metastases
    Robbert J de Haas
    Centre Hepato Biliaire, AP HP Hopital Paul Brousse, Villejuif, France
    Ann Surg Oncol 17:1010-23. 2010
    ....
  50. ncbi request reprint The doxorubicin-streptozotocin combination for the treatment of advanced well-differentiated pancreatic endocrine carcinoma; a judicious option?
    Th Delaunoit
    Department of Gastroenterology, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France
    Eur J Cancer 40:515-20. 2004
    ..7 months, and suggests that it could be considered as a valid option in first-line therapy...
  51. ncbi request reprint Functional results and quality of life for patients with very low rectal cancer undergoing coloanal anastomosis or perineal colostomy with colonic muscular graft
    M Pocard
    Department of Surgical Oncology, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
    Eur J Surg Oncol 33:459-62. 2007
    ..The aim of this study was to compare functional results and quality of life (QoL) of two salvage techniques: coloanal anastomosis (CAA) or perineal reconstruction after abdominoperineal resection for very low rectal cancer...
  52. doi request reprint [Use of sorafenib (Nexavar) in the treatment of hepatocellular carcinoma: PRODIGE AFEF recommendations]
    V Boige
    Departement de Medecine, Institut Gustave Roussy, 39, rue Camille Desmoulins, 94805 Villejuif Cedex, France
    Gastroenterol Clin Biol 32:3-7. 2008
  53. ncbi request reprint Adjuvant chemotherapy for colon cancer
    M Ducreux
    Gastroenterology Unit, Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Best Pract Res Clin Gastroenterol 16:283-98. 2002
    ..Current clinical trials are evaluating the role of non-fluorinated pyrimidine agents in an adjuvant setting...
  54. ncbi request reprint Human pharmacokinetic study of heated intraperitoneal oxaliplatin in increasingly hypotonic solutions after complete resection of peritoneal carcinomatosis
    D Elias
    Department of Surgical Oncology, Institut Gustave Roussy, Villejuif, France
    Oncology 63:346-52. 2002
    ..p.) oxaliplatin (LOHP) solution and its safety profile in increasingly hypotonic solutions. This is the first clinical study of i.p. chemohyperthermia with hypotonic solutions...
  55. ncbi request reprint Results of 136 curative hepatectomies with a safety margin of less than 10 mm for colorectal metastases
    D Elias
    Department of Oncologic Surgery, Institut Gustave Roussy, Comprehensive Cancer Centre, Villejuif, France
    J Surg Oncol 69:88-93. 1998
    ..The true impact of the width of the margin on the prognosis is unclear...
  56. ncbi request reprint Treatment of advanced gastric cancer: where we are in 2003
    Michel Ducreux
    Onkologie 26:214-5. 2003
  57. ncbi request reprint Hyperthermic intraperitoneal chemotherapy in the treatment of peritoneal carcinomatosis of digestive and peritoneal origin: rationale
    G Liberale
    Department of Surgical Oncology, Gustave Roussy Institute IGR, Centre de lutte contre le cancer, Villejuif, France
    Acta Chir Belg 106:291-6. 2006
    ..Those patients should no longer be considered as patients with a terminal disease but as patients with a potentially treatable localized disease...
  58. ncbi request reprint Carcinoma of an unknown primary site: a chemotherapy strategy based on histological differentiation--results of a prospective study
    M Saghatchian
    Institut Gustave Roussy, Villejuif, France
    Ann Oncol 12:535-40. 2001
    ..To evaluate the efficacy and toxicity of a chemotherapy strategy based on histological differentiation, for patients with carcinoma of unknown primary site...
  59. doi request reprint Results of systematic second-look surgery plus HIPEC in asymptomatic patients presenting a high risk of developing colorectal peritoneal carcinomatosis
    D Elias
    Department of Surgical Oncology, Institut Gustave Roussy, Cedex, France
    Ann Surg 254:289-93. 2011
    ....
  60. ncbi request reprint Phase I, dose-finding, and pharmacokinetic study of raltitrexed combined with oxaliplatin in patients with advanced cancer
    K Fizazi
    Institut Gustave Roussy, Villejuif, and AstraZeneca Pharmaceuticals, Cergy, France
    J Clin Oncol 18:2293-300. 2000
    ....
  61. ncbi request reprint Treatment of synchronous peritoneal carcinomatosis and liver metastases from colorectal cancer
    D Elias
    Department of Oncologic Digestive Surgery and Digestive Oncology, Institut Gustave Roussy, Cancer Center Hospital, rue Camille Desmoulins, 94805 Villejuif Cedex, France
    Eur J Surg Oncol 32:632-6. 2006
    ..To report our experience of peritoneal carcinomatosis (PC) discovered during abdominal exploration in patients with liver metastases (LM)...
  62. ncbi request reprint Cost-effectiveness analysis of first-line chemotherapies in metastatic colorectal cancer. Results of the Fédération Francophone de Cancérologie Digestive (FFCD) 9601 randomized trial
    Isabelle Borget
    Gustave Roussy Institute, Villejuif, France
    Oncology 71:40-8. 2006
    ..The aim of the study was to evaluate the efficacy and the costs of three regimens as compared to HD-LV5FU2: raltitrexed (R), LV5FU2 with a lower dose of folinic acid (LD-LV5FU2), and weekly infusional 5FU (WI-FU)...
  63. doi request reprint Impact of primary tumour resection on survival of patients with colorectal cancer and synchronous metastases treated by chemotherapy: results from the multicenter, randomised trial Fédération Francophone de Cancérologie Digestive 9601
    F Ferrand
    Institut Gustave Roussy, Gastro Intestinal Unit, Department of Oncologic Medicine, Universite Paris Sud, Villejuif, France
    Eur J Cancer 49:90-7. 2013
    ..To assess the impact of primary tumour resection on overall survival (OS) of patients diagnosed with stage IV colorectal cancer (CRC)...
  64. ncbi request reprint Results of lymphadenectomy for obvious lateroaortic lymph node metastases from colorectal primaries
    D Elias
    Department of Digestive Oncological Surgery, Medical Oncology, and Radiotherapy, Institut Gustave Roussy, Comprehensive Cancer Center, Villejuif, France
    Hepatogastroenterology 48:123-7. 2001
    ..To analyze the results of surgery for macroscopically or radiologically obvious (i.e., easily detectable by computed tomography scan or by palpation) synchronous or metachronous lateroaortic lymph node metastases from colorectal primaries...
  65. ncbi request reprint Gastric linitis adenocarcinoma and carcinomatous meningitis: an infrequent but aggressive association--report of four cases
    T Delaunoit
    Service d Oncologie digestive Médicale, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 12:869-71. 2001
    ..Furthermore, the diagnosis of CM must be done as soon as possible because of the clear effectiveness of a therapeutic approach on the improvement of symptoms and quality of life...
  66. ncbi request reprint [Positron emission tomography and gastrointestinal oncology]
    Michel Ducreux
    Institut Gustave Roussy, rue Camille Desmoulins, 94805 Villejuif Cedex
    Gastroenterol Clin Biol 27:B71-8. 2003
  67. ncbi request reprint [What changes were made in the National Thesaurus of Gastrointestinal Cancer in 2005?]
    Jean Louis Legoux
    Services d Hépato gastroentérologie, Hopital Haut Leveque, CHU de Bordeaux, Pessac
    Gastroenterol Clin Biol 30:1191-5. 2006
  68. ncbi request reprint Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedules
    Julien Taieb
    Service d Hepato gastro enterologie, Groupe Hospitalier Pitie Salpetriere, Paris, France
    Cancer 98:2664-70. 2003
    ..Therefore, the authors evaluated the activity and toxicity of two such combinations in patients with HCC...
  69. doi request reprint KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab
    Astrid Lievre
    L Institut National de la Santé et de la Recherche Médicale U775, Universite Paris Descartes, 45 Rue des Saints Peres, 75006 Paris, France
    J Clin Oncol 26:374-9. 2008
    ..The aim of this study was to validate, in an independent larger series of 89 patients, the prognostic value of KRAS mutations on response to cetuximab and survival...
  70. ncbi request reprint [Clinical practice guideline: 2003 update of Standards, Options et Recommendations for first line palliative chemotherapy in patients with metastatic colorectal cancer (summary report)]
    Thierry Conroy
    Centre Alexis Vautrin, Nancy
    Bull Cancer 91:759-68. 2004
    ..The main objective is the development of clinical practice guidelines to improve the quality of health care and the outcome of cancer patients...
  71. ncbi request reprint Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution
    D Elias
    Department of Surgical Oncology, Institut Gustave Roussy Comprehensive Cancer Center, Villejuif, France
    Ann Oncol 13:267-72. 2002
    ..Oxaliplatin has demonstrated significant activity in advanced colorectal cancer, and this is the first publication concerning its intraperitoneal administration...
  72. doi request reprint Prediction and diagnosis of bone metastases in well-differentiated gastro-entero-pancreatic endocrine cancer: a prospective comparison of whole body magnetic resonance imaging and somatostatin receptor scintigraphy
    S Leboulleux
    Department of Nuclear Medicine and Endocrine Oncology, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
    J Clin Endocrinol Metab 93:3021-8. 2008
    ....
  73. pmc Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours
    E Baudin
    , Institut Gustave Roussy, Villejuif, France
    Br J Cancer 78:1102-7. 1998
    ..01). Among six patients with NET followed for 11-37 months, CgA appeared to be a better marker of tumour evolution than NSE. We suggest that CgA ought to be the only general marker screened in NET patients...
  74. doi request reprint A prolonged follow-up provides new insights into locally advanced pancreatic cancer treatment
    D Goere
    Department of Surgical Oncology, Institut Gustave Roussy, 39, rue Camille Desmoulins, 94805, Villejuif Cedex, France
    Gastroenterol Clin Biol 32:649-52. 2008
    ....
  75. ncbi request reprint [5-FU, folinic acid and cisplatin (LV5FU2-P) for unresectable pancreatic cancer]
    Julien Taieb
    Departement de Medecine, Institut Gustave Roussy, Villejuif, France
    Gastroenterol Clin Biol 26:605-9. 2002
    ..To prospectively evaluate efficacy and tolerance of the 5-fluorouracil + folinic acid + cisplatin (LV5FU2-P) combination in the treatment of unresectable pancreatic carcinoma...
  76. ncbi request reprint Liver resection (and associated extrahepatic resections) for metastatic well-differentiated endocrine tumors: a 15-year single center prospective study
    Dominique Elias
    Department of Surgical Oncology, Comprehensive Cancer Center, Institut Gustave Roussy, rue Camille Desmoulins, 94805 Villejuif Cedex, France
    Surgery 133:375-82. 2003
    ..However, surveillance alone yields only a 22% 5-year survival when metastases occur. The aim of this study was to determine the results of hepatic and extra hepatic resections and to clarify the indications of surgery...
  77. ncbi request reprint Sentinel lymph nodes of colorectal carcinoma: reappraisal of 123 cases
    Gabriel Liberale
    Departement de Chirurgie Oncologique, CHU Charles Nicolle, Rouen
    Gastroenterol Clin Biol 31:281-5. 2007
    ..The SLN technique may be used to guide surgical resection (lymph mapping), restrict the lymph node analysis solely to the SLN (accuracy) and upgrade tumor staging when micrometastases are specifically detected in the SLN...
  78. ncbi request reprint Hepatic resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy
    Rene Adam
    Centre Hépato Biliaire and the Department of Medical Oncology, Assistance Publique Hopitaux de Paris, France
    J Clin Oncol 25:4593-602. 2007
    ..This study was performed to determine the post-cetuximab resectability rate and to examine postoperative outcomes for these heavily pretreated patients...
  79. ncbi request reprint Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203
    Jean Pierre Gerard
    Centre Antoine Lacassagne, Radiotherapy Department, Nice, France
    J Clin Oncol 24:4620-5. 2006
    ..In 1992, preoperative radiotherapy was considered in France as the standard treatment for T3-4 rectal cancers. The present randomized trial compares preoperative radiotherapy with chemoradiotherapy...
  80. ncbi request reprint Combined radiotherapy, 5-fluorouracil continuous infusion and weekly oxaliplatin in advanced rectal cancer: a phase I study
    Eric Francois
    Department of Medical Oncology, Centre Antoine Lacassagne, Avenue de Valombrose, 06189 Nice, Cedex 2, France
    Eur J Cancer 41:2861-7. 2005
    ..The good safety profile of the regimen, associated with promising results in terms of histological response, suggest that the regimen could be developed in future phase II/III studies...
  81. ncbi request reprint [Linitis of the colon with peritoneal carcinosis treated with cytoreductive surgery and intraperitoneal hyperthermic chemotherapy]
    Hatem Salloum
    Gastroenterol Clin Biol 31:68-9. 2007
  82. ncbi request reprint Feasibility of preoperative combined radiation therapy and chemotherapy with 5-fluorouracil and cisplatin in potentially resectable pancreatic adenocarcinoma: The French SFRO-FFCD 97-04 Phase II trial
    Francoise Mornex
    département de radiothérapie oncologie, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Lyon France
    Int J Radiat Oncol Biol Phys 65:1471-8. 2006
    ..Neoadjuvant chemoradiotherapy might offer potential benefits regarding local and systemic control and survival. This multi-institutional Phase II trial explored the feasibility of preoperative chemoradiation in this situation...
  83. doi request reprint Immunogenic death of colon cancer cells treated with oxaliplatin
    A Tesniere
    INSERM, U848, Villejuif, France
    Oncogene 29:482-91. 2010
    ..In conclusion, OXP induces immunogenic death of CRC cells, and this effect determines its therapeutic efficacy in CRC patients...
  84. doi request reprint Endocrine pancreatic tumours: which are the most useful MRI sequences?
    C Caramella
    Department of Radiology, Institut Gustave Roussy, 39, rue Camille Desmoulins, 94805, Villejuif Cedex, France
    Eur Radiol 20:2618-27. 2010
    ..To determine magnetic resonance imaging (MRI) signal and enhancement characteristics of endocrine pancreatic tumours (ETPs) and which MR sequences show them most consistently...
  85. doi request reprint The long-term impact of hyperthermic intraperitoneal chemotherapy on survivors treated for peritoneal carcinomatosis: a cross-sectional study
    Franck Zenasni
    Department of Psycho oncology, Institut Gustave Roussy, Villejuif, Paris, France
    Support Care Cancer 17:1255-61. 2009
    ..Hyperthermic intraperitoneal chemotherapy (HIPEC) after complete surgical resection is currently accepted as a therapeutic option for peritoneal carcinomatosis. However, considerable morbidity is reported after HIPEC...
  86. ncbi request reprint Malignant gastroduodenal obstruction: palliation with self-expanding metallic stents
    Bertrand Bessoud
    Department of Medical and Interventional Imaging, Institut Gustave Roussy, Villejuif, France
    J Vasc Interv Radiol 16:247-53. 2005
    ..To evaluate the feasibility, efficacy, and tolerance of self-expanding metallic stent insertion under fluoroscopic guidance for palliation of symptoms related to malignant gastroduodenal obstruction...
  87. ncbi request reprint [Colorectal cancer: contribution of new diagnostic tools]
    Clarisse Dromain
    Departement d Imagerie, Institut Gustave Roussy, 94805 Villejuif
    Rev Prat 54:151-4. 2004
    ..It however will be necessary, in the years to come, to precisely evaluate the interest of this new method of imagery in the diagnosis of colorectal tumors, or in the follow-up of certain patients...
  88. ncbi request reprint Cetuximab plus gemcitabine-oxaliplatin (GEMOX) in patients with refractory advanced intrahepatic cholangiocarcinomas
    Bernard Paule
    Hepato Biliary Center, Assistance Publique Hopitaux de Paris, Hopital Paul Brousse, Faculté de Médecine Paris Sud 11, Villejuif, France
    Oncology 72:105-10. 2007
    ..To assess the efficacy and safety of cetuximab in the palliative treatment of patients with intrahepatic cholangiocarcinomas (CCA) unresponsive to first-line gemcitabine-oxaliplatin (GEMOX) pretreatment...
  89. ncbi request reprint Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancer
    David Fallik
    Department of Medicine, Institut Gustave Roussy, Centre National de la Recherche Scientifique Unité Mixte de Recherche 1598, Villejuif, France
    Cancer Res 63:5738-44. 2003
    ..001), indicating that MSI-driven inactivation of target genes modifies tumor chemosensitivity. Our observations allowed us to define the first useful predictive criteria for irinotecan response in patients with colorectal cancer...
  90. ncbi request reprint Safety of cisplatin combined with continuous 5-FU versus bolus 5-FU and leucovorin, in metastatic gastrointestinal cancer (FFCD 9404 randomised trial)
    Jacqueline Duffour
    CRLC Val d Aurelle Paul Lamarque, 34298 Montpellier, France
    Anticancer Res 26:3877-83. 2006
    ..FP (5-FU combined with Cisplatin) as a first line chemotherapy in advanced oesophageal, gastric and pancreatic cancer...
  91. ncbi request reprint An appendix carcinoid tumor in a patient with hereditary nonpolyposis colorectal cancer
    Catherine Miquel
    Department of Pathology, Saint Anne Hospital, Paris, France
    Hum Pathol 35:1564-7. 2004
    ..Interestingly, the adenocarcinoma exhibited an MSI phenotype but the carcinoid tumor did not, indicating that these 2 tumors arose through different molecular pathways...
  92. ncbi request reprint Oxaliplatin combined with 5-FU in second line treatment of advanced pancreatic adenocarcinoma. Results of a phase II trial
    Emmanuel Mitry
    CHU Ambroise Pare, Boulogne
    Gastroenterol Clin Biol 30:357-63. 2006
    ..The efficacy and benefit of second-line chemotherapy in advanced pancreatic adenocarcinoma has never been demonstrated although it is regularly used...
  93. doi request reprint Performance of (18)fluorodeoxyglucose-positron emission tomography and somatostatin receptor scintigraphy for high Ki67 (≥10%) well-differentiated endocrine carcinoma staging
    Ronan Abgral
    Department of Nuclear Medicine, University Hospital of Brest, 29200 Brest, France
    J Clin Endocrinol Metab 96:665-71. 2011
    ....
  94. ncbi request reprint Hepatic tumors treated with percutaneous radio-frequency ablation: CT and MR imaging follow-up
    Clarisse Dromain
    Department of Radiology, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France
    Radiology 223:255-62. 2002
    ....
  95. doi request reprint Prognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well-differentiated endocrine carcinoma
    Cosimo Durante
    Service de Médecine Nucléaire et de Cancérologie Endocrinienne, Institut Gustave Roussy, Universite Paris XI, 94805 Villejuif Cedex, France
    Endocr Relat Cancer 16:585-97. 2009
    ..This study enables the stratification of metastatic GEP WDEC patients into distinct risk groups. These risk categories can be used to tailor therapeutic approaches and also to design and interpret clinical trials...
  96. ncbi request reprint Trans-catheter arterial chemoembolization as first-line treatment for hepatic metastases from endocrine tumors
    Alain Roche
    Service de Radiologie Interventionnelle, Institut Gustave Roussy, rue Camille Desmoulins 39, 94805 Villejuif Cedex, France
    Eur Radiol 13:136-40. 2003
    ..Long-term palliation is possible in unresectable liver metastases from digestive neuroendocrine tumors with a few sessions of TACE as first-line and eventually exclusive treatment...
  97. doi request reprint Prolonged survival of initially unresectable hepatic colorectal cancer patients treated with hepatic arterial infusion of oxaliplatin followed by radical surgery of metastases
    Diane Goere
    Department of Surgical Oncology, Institut Gustave Roussy, Villejuif Cedex, France
    Ann Surg 251:686-91. 2010
    ..The aim of this study was to analyze the impact of hepatic arterial infusion (HAI) of oxaliplatin with systemic 5-Fluorouracil and leucovorin on patients with isolated unresectable liver metastases...
  98. ncbi request reprint Results of R0 resection for colorectal liver metastases associated with extrahepatic disease
    Dominique Elias
    Department of Surgical Oncology, Gustave Roussy Institute, Villejuif, France
    Ann Surg Oncol 11:274-80. 2004
    ..This study reports the long-term outcome and prognostic factors of patients undergoing extrahepatic disease resection simultaneously with hepatectomy for liver metastases...
  99. ncbi request reprint [Colorectal cancer: prognostic molecular markers]
    Valerie Boige
    Unité de Gastro Entérologie, Institut Gustave Roussy, Villejuif
    Gastroenterol Clin Biol 28:21-32. 2004
  100. ncbi request reprint Regional chemotherapeutic techniques for liver tumors: current knowledge and future directions
    Dominique Elias
    Division of Surgical Oncology, Department of Surgery, Gustave Roussy Institute, rue Camille Desmoulins, 94805, Villejuif, France
    Surg Clin North Am 84:607-25. 2004
    ..At the same time, resectability rates are increasing with the assistance of local ablative physical treatments such as radiofrequency, resulting in an improvement of patients' median survival rates and quality of life...
  101. ncbi request reprint Dosage adjustment and pharmacokinetic profile of irinotecan in cancer patients with hepatic dysfunction
    Eric Raymond
    Department of Medicine, Gustave Roussy Institute, Villejuif, France
    J Clin Oncol 20:4303-12. 2002
    ..To determine the recommended dose (RD) and the pharmacokinetic profile of irinotecan and its metabolites in cancer patients with hyperbilirubinemia...